Insider · CIK 0001663253

Gangloff Scott A.

Reports to the SEC for 2 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001663253

Forms 4 and 5

Insider transactions

16 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Technology Officer	DDisposition to Issuer	−17.8K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Technology Officer	DDisposition to Issuer	−205K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Technology Officer	DDisposition to Issuer	−73.7K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Technology Officer	DDisposition to Issuer	−21.3K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Technology Officer	DDisposition to Issuer	−5,088 sh	—	—	0
2025-08-15	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Technology Officer	MExercise/Conversion	+2,600 sh	$19.62	+$51K	26,351
2025-08-15	Akero Therapeutics, Inc.Stock option (Right to Buy)M Exercise/Conversion	Chief Technology Officer	MExercise/Conversion	−2,600 sh	—	—	17,784
2025-06-30	Akero Therapeutics, Inc.A Award	Chief Technology Officer	AAward	+299 sh	$23.87	+$7,136.532	23,751
2025-06-18	Akero Therapeutics, Inc.S Sale	Chief Technology Officer	SSale	−848 sh	$54.84	−$46.5K	23,452
2024-12-16	Akero Therapeutics, Inc.A Award	Chief Technology Officer	AAward	+24.3K sh	—	—	24,300
2024-12-16	Akero Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Technology Officer	AAward	+73.7K sh	—	—	73,700
2024-04-29	Akero Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Technology Officer	AAward	+225K sh	—	—	225,000
2016-12-21	OTLKOutlook Therapeutics, Inc.A Award	SVP, Development & Mfrg	AAward	+40K sh	—	—	118,573
2016-11-11	OTLKOutlook Therapeutics, Inc.S Sale	SVP, Development & Mfrg	SSale	−37.4K sh	$3.75	−$140K	78,573
2016-11-09	OTLKOutlook Therapeutics, Inc.C Conversion	SVP, Development & Mfrg	CConversion	−116K sh	—	—	0
2016-11-09	OTLKOutlook Therapeutics, Inc.M Exercise/Conversion	SVP, Development & Mfrg	MExercise/Conversion	+116K sh	—	—	115,942

Recent filings

Accepted (ET)
Dec 94
Gangloff Scott A.0001193125-25-312111
SEC(opens sec.gov)
Aug 194
Gangloff Scott A.0000950170-25-110352
SEC(opens sec.gov)
Jul 24
Gangloff Scott A.0000950170-25-093317
SEC(opens sec.gov)
Jun 204
Gangloff Scott A.0000950170-25-088640
SEC(opens sec.gov)
Dec 184
Gangloff Scott A.0000950170-24-138138
SEC(opens sec.gov)
May 14
Gangloff Scott A.0000950170-24-051488
SEC(opens sec.gov)
Dec 224
Oncobiologics, Inc.0001209191-16-156579
SEC(opens sec.gov)
Nov 144
Oncobiologics, Inc.0001214659-16-014641
SEC(opens sec.gov)

Companies

Address

C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350

SOUTH SAN FRANCISCO, CA, 94080